Liposomal therapies in oncology: does one size fit all? Isabel SousaFilipa RodriguesPaula Soares Review Article 16 August 2018 Pages: 741 - 755
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors Mary E. R. O’BrienDebashis SarkerJames Spicer Original Article Open access 07 August 2018 Pages: 757 - 766
Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer Ippokratis MessaritakisMaria SfakianakiVassilis Georgoulias Original Article 09 August 2018 Pages: 767 - 775
A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity Soo Jie ChungSung-Yoon KangHye-Ryun Kang Original Article 13 August 2018 Pages: 777 - 785
Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy Negin FarshchianAvisa AlaviNasrin Moradian Original Article 13 August 2018 Pages: 787 - 793
In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia Hisham QosaBrittany R. AvarittDonna A. Volpe Original Article 13 August 2018 Pages: 795 - 802
Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces Sandeepraj PusalkarMihaela PlesescuSwapan Chowdhury Original Article 20 August 2018 Pages: 803 - 814
Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment Kelong TaoMeng HeYaoqing Li Original Article 21 August 2018 Pages: 815 - 827
A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer Min HuangHong ZhuYing Huang Original Article 24 August 2018 Pages: 829 - 838
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane Hironaga SatakeTamotsu SagawaAkihito Tsuji Original Article Open access 30 August 2018 Pages: 839 - 845
Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers Vassilios AslanisJianping ZhangTaoufik Ouatas Original Article 31 August 2018 Pages: 847 - 855
Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma Ayako Iida-UenoMasaru EnomotoNorifumi Kawada Original Article 03 September 2018 Pages: 857 - 864
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre Michael MoloneyDavid FaulknerMichael Michael Original Article 03 September 2018 Pages: 865 - 876
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement Elena FountzilasElangovan KrishnanApostolia-Maria Tsimberidou Original Article 04 September 2018 Pages: 877 - 885
Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood Z. LiuJ. MartinD. M. Thomas Original Article 11 September 2018 Pages: 887 - 898
A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects Vladimir HanesVincent ChowRichard Markus Clinical Trial Report Open access 29 September 2018 Pages: 899 - 905
A comparison of the quality of informed consent for phase I oncology trials over a 30-year period Laeeq MalikJames Cooper Short Communication 27 August 2018 Pages: 907 - 910
Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models Udai BanerjiNivedita SainPaul Workman Correction 01 September 2018 Pages: 911 - 912